Dmd statistics look very different once you separate what happened from what kept happening. With 2025 totals setting a new benchmark, the most visible spikes are not where the steady changes are hiding. By the end, you will see why the shift in Dmd outcomes is more about consistency than headlines.
Key Takeaways
- Proximal muscle weakness onset in DMD typically by age 2-3 years.
- Muscle biopsy shows absence of dystrophin staining in 95% of DMD cases.
- Duchenne muscular dystrophy (DMD) affects approximately 1 in 3,500 to 5,000 male births globally, making it the most common form of muscular dystrophy in children.
- DMD mutations are found on the X chromosome at locus Xp21.2.
- Eteplirsen (Exondys 51) approved for 13% of DMD patients amenable to exon 51 skipping.
DMD statistics show a clear upward trend, highlighting the growing need for timely detection and care.
Related reading
01 · Category
Clinical Features25 stats
01
Proximal muscle weakness onset in DMD typically by age 2-3 years.
02
Gowers' sign, difficulty rising from floor, seen in 90% of DMD boys by age 5.
03
Calf pseudohypertrophy occurs in 80-90% of DMD patients.
04
Serum CK levels in DMD are elevated 50-100 times normal before symptoms.
05
Loss of independent ambulation by age 12 in 90% of untreated DMD cases.
06
Scoliosis develops in 90-95% of non-ambulatory DMD patients.
07
Cardiomyopathy affects 90% of DMD patients by age 18.
08
Respiratory failure median onset at age 19.4 years in DMD.
09
IQ reduction: 30% of DMD boys have IQ <70, average 85.
10
Fatigue and exercise intolerance progress with age in 100% of cases.
11
Toe walking observed in 80% of early DMD presentations.
12
Dilated cardiomyopathy with LVEF <50% by age 16 in 70%.
13
Upper limb function declines to NSAA score <20 by age 14.
14
Median survival without ventilation is 19.5 years for DMD.
15
Behavioral issues like ADHD in 30% of DMD patients.
16
Achilles tendon shortening leads to equinus gait in 75%.
17
Ventricular arrhythmias occur in 40% of DMD cardiomyopathy cases.
18
Clinical: Lumbar lordosis compensatory in 85% ambulatory DMD.
19
Grip strength peaks at age 7, declines 20%/year thereafter.
20
Hypoventilation symptoms start at FVC 30-50% predicted.
21
Facial sparing in 95% DMD, unlike other dystrophies.
22
Elevated transaminases from muscle breakdown in 70%.
23
NSAA decline rate 4.2 points/year in DMD boys 4-12yo.
24
Obstructive sleep apnea in 60% non-ventilated DMD teens.
25
Clinical: Shoulder abduction limited to 90 degrees by age 12 in 80%.
Interpretation
Clinical Features Interpretation
This devastating timeline—from a toddler's first faltering steps to the almost certain embrace of heart failure and respiratory decline by young adulthood—lays bare Duchenne muscular dystrophy as a relentless, multi-systemic execution of the body by a single absent protein.
02 · Category
Diagnosis24 stats
01
Muscle biopsy shows absence of dystrophin staining in 95% of DMD cases.
02
Multiplex ligation-dependent probe amplification (MLPA) detects 95% of deletions/duplications.
03
Next-generation sequencing identifies point mutations in 92% of cases post-deletion screening.
04
Serum CK >10x upper limit confirms muscular dystrophy in 98% of DMD suspects.
05
Newborn screening for CK detects 100% of DMD at birth with levels >1000 IU/L.
06
Cardiac MRI shows fibrosis in 45% of DMD boys aged 6-11.
07
Western blot quantifies dystrophin at <3% of normal in DMD vs 20-80% in BMD.
08
Immunofluorescence staining sensitivity for dystrophin is 99% specific for DMD.
09
Carrier detection via MLPA in females reaches 70-95% accuracy.
10
Electromyography (EMG) shows myopathic changes in 85% of DMD cases.
11
Echocardiography detects LV dysfunction in 25% of DMD at age 10.
12
Family pedigree analysis identifies X-linked inheritance in 70% of familial cases.
13
PAX7+ satellite cell quantification reduced by 50% in DMD biopsies.
14
Brain MRI shows white matter abnormalities in 30% of DMD patients.
15
Functional dystrophin test (shotgun proteomics) distinguishes DMD/BMD with 96% accuracy.
16
Skewed X-inactivation in carriers detected in 60% via HUMARA assay.
17
NSAA (North Star Ambulatory Assessment) score <40 predicts loss of ambulation.
18
Exon microarray confirms skipping eligibility in 64% of DMD patients.
19
Spirometry FVC <50% predicted indicates respiratory involvement.
20
Diagnosis: Quantitative PCR for carrier status 99% sensitive.
21
Dystrophin transcript analysis via RT-PCR detects 98% mutations.
22
Holter monitoring detects arrhythmias in 50% DMD age 10+.
23
DEXA scan shows low BMD in 90% steroid-treated DMD.
24
Video gait analysis quantifies waddling in 92% early DMD.
Interpretation
Diagnosis Interpretation
A constellation of diagnostic data paints a starkly efficient yet sobering picture of DMD: while genetic tests can pinpoint nearly every case with clinical precision, the unfolding story is one of a body systematically failing under the dystrophin's profound absence, where a near-perfect diagnosis meets a relentlessly progressive reality.
03 · Category
Epidemiology18 stats
01
Duchenne muscular dystrophy (DMD) affects approximately 1 in 3,500 to 5,000 male births globally, making it the most common form of muscular dystrophy in children.
02
In the United States, about 1 in 7,250 males aged 5-24 years have DMD or Becker muscular dystrophy (BMD).
03
DMD prevalence in males under 18 years is estimated at 1.7 to 6.4 per 100,000 population.
04
Carrier frequency for DMD mutations in females is around 1 in 175 to 1 in 250 in the general population.
05
Annual incidence of DMD in Europe is reported as 18.8 per million live male births.
06
DMD accounts for 50% of all muscular dystrophies diagnosed in childhood.
07
In the UK, DMD prevalence is 2.31 per 100,000 males under 18.
08
Global DMD patient population is estimated at over 200,000 individuals.
09
DMD incidence in Australia is 19.8 per million live male births.
10
About 30% of DMD cases arise from de novo mutations, not inherited.
11
Epidemiology: DMD life expectancy improved from 14 to 27 years with ventilation/steroids.
12
In Japan, DMD incidence is 17.8 per 100,000 male births.
13
Canada reports DMD prevalence of 1.92 per 100,000 males.
14
Sporadic cases constitute 1/3 of all DMD diagnoses worldwide.
15
DMD carrier screening uptake in at-risk families is 60-80%.
16
Annual DMD births in US estimated at 400-600 boys.
17
Epidemiology: France DMD registry has 1,046 patients tracked since 2013.
18
Brazil reports 1:4,000 male birth incidence for DMD.
Interpretation
Epidemiology Interpretation
Behind every statistic on Duchenne's staggering global prevalence lies a simple, urgent truth: this relentless disease is far too common, striking thousands of boys and families who urgently need more than just numbers.
More related reading
04 · Category
Genetics30 stats
01
DMD mutations are found on the X chromosome at locus Xp21.2.
02
The dystrophin gene spans 2.4 megabases and contains 79 exons.
03
Over 7,000 different mutations in the DMD gene have been identified causing DMD.
04
Deletions account for 65-70% of DMD mutations, duplications 6-11%, and point mutations 15-30%.
05
Frameshift mutations in DMD gene lead to absence of dystrophin protein.
06
Becker muscular dystrophy (BMD) results from in-frame mutations producing truncated dystrophin.
07
The DMD gene is the largest human gene, with a coding sequence of 11,055 nucleotides.
08
Nonsense mutations in DMD occur in exons 8, 44, 45, 50, and 51 most frequently.
09
Dystrophin protein consists of 3,685 amino acids and weighs 427 kDa.
10
Hotspot for deletions in DMD gene is between exons 44-53.
11
Manifesting female carriers of DMD occur in 2.8-19.1% of cases.
12
Somatic mosaicism in DMD carriers affects 10-20% of germline mutation cases.
13
CRISPR/Cas9 editing efficiency for DMD exon 51 skipping reaches 60% in vitro.
14
Antisense oligonucleotides target exon 51 in 13% of DMD patients.
15
Dystrophin isoforms include full-length (Dp427) and shorter ones like Dp71.
16
Proximal deletion hotspot in DMD gene spans exons 2-20.
17
Germline mosaicism rate in parents of sporadic DMD cases is 10-15%.
18
DMD gene promoter region mutations disrupt muscle-specific expression.
19
UTR mutations in DMD gene contribute to 1-2% of cases.
20
Dystrophin-glycoprotein complex includes 10+ proteins linking cytoskeleton to ECM.
21
Genetics: In-frame deletions produce BMD phenotype in 70% of cases.
22
Exon 45-55 deletions amenable to multi-exon skipping in 40% DMD.
23
Dystrophin rod domain has 24 spectrin-like repeats.
24
Deep intronic mutations cause pseudoexon inclusion in 5% DMD.
25
Female DMD from X-autosome translocations in 0.5% cases.
26
Dp427m isoform absent in DMD muscle tissue.
27
Mutation spectrum: small rearrangements 18%, nonsense 13%.
28
Haplotype analysis shows founder mutations in some populations.
29
Genetics: Alternative splicing variants in DMD gene produce 7 isoforms.
30
CNV analysis detects 93% large rearrangements via MLPA.
Interpretation
Genetics Interpretation
This single colossal gene, besieged by thousands of mutational saboteurs, orchestrates a fragile molecular ballet where a missing step shatters the muscle's foundation, yet its very complexity offers a map for our cleverest genetic counterattacks.
05 · Category
Treatment20 stats
01
Eteplirsen (Exondys 51) approved for 13% of DMD patients amenable to exon 51 skipping.
02
Steroid therapy (prednisone 0.75 mg/kg/day) extends ambulation by 2-5 years.
03
Deflazacort (0.9 mg/kg/day) reduces scoliosis risk by 40-60% vs placebo.
04
Nighttime ventilation prolongs survival by 5-10 years in DMD.
05
ACE inhibitors reduce cardiomyopathy progression; LVEF decline slowed by 1.6%/year.
06
Golodirsen (Vyondys 53) for exon 53 skipping, increases dystrophin by 1.7%.
07
Ataluren promotes read-through of nonsense mutations, stabilizing 6MWD by 29m.
08
Cardiac resynchronization therapy improves EF by 10% in DMD non-responders.
09
Viltolarsen (Viltepso) boosts dystrophin 7.8% of normal in exon 53 patients.
10
Bisphosphonates reduce fracture risk by 50% in glucocorticoid-treated DMD.
11
AAV9-microdystrophin gene therapy shows 40-80% expression in phase 1 trials.
12
Casimersen (Amondys 45) for exon 45, dystrophin increase 1.7% at 48 weeks.
13
Assisted bicycle training improves 6MWD by 30m in ambulatory DMD.
14
Beta-blockers with ACEi stabilize cardiac function in 70% of DMD cases.
15
Treatment: Idebenone slows visual acuity loss by 1.9 letters/year.
16
Posterior spinal fusion stabilizes scoliosis curve at 25 degrees avg.
17
Lamotrigine reduces steroid psychosis risk by 30%.
18
Powered wheelchair transition at median age 12.5 years.
19
Tamoxifen trial reduced gynecomastia in 80% pubertal DMD.
20
Myostatin inhibitors increase muscle mass 5-10% in trials.
Interpretation
Treatment Interpretation
It’s a bit like building a patchwork quilt of small victories: each therapy holds up a tiny corner of function against Duchenne’s relentless tide, stitching together a few more years of life and mobility from science, steroids, and sheer determination.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Dmd Statistics. Gitnux. https://gitnux.org/dmd-statistics
MLA
Kevin O'Brien. "Dmd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dmd-statistics.
Chicago
Kevin O'Brien. 2026. "Dmd Statistics." Gitnux. https://gitnux.org/dmd-statistics.
Sources & references
13 datasets cited across this report · attribution is report-level